Seeking Alpha
Profile| Send Message| ()  

Following is a brief snapshot of stock market performance of top quarterly buys (as per 13F filing) from legendry investor George Soros:

Top New Buys

Stock

Symbol

Shares Bought Last Quarter

31 March Price

17 June Price

% Return

Adecoagro SA

AGRO

27,158,693

13.48

12.3

-8.8%

Visteon Corp

VC

2,134,106

62.49

64.9

3.9%

Charter Communications, Inc

CHTR

750,609

50.63

56.81

12.2%

Itau Unibanco Banco Holding SA

ITUB

1,351,950

24.05

22.03

-8.4%

HCA Hldgs Inc

HCA

700,000

33.87

34.59

2.1%

Wabash National Corp

WNC

1,900,000

11.58

8.8

-24.0%

Baidu Inc

BIDU

139,700

137.81

117.68

-14.6%

BE Aerospace Inc

BEAV

507,600

35.53

37.93

6.8%

Noble Energy Inc

NBL

180,000

96.65

83.42

-13.7%

Ferro Corp

FOE

1,021,700

16.59

12.13

-26.9%

Top Position Increases

Stock

Symbol

Shares Bought Last Quarter

31 March Price

17 June Price

% Return

Wells Fargo & company

WFC

2,936,300

31.71

27.33

-13.8%

CVS Caremark Corporation

CVS

2,639,376

34.32

37.33

8.8%

Citigroup Inc

C

1,866,823

44.2

38.3

-13.3%

Danaher Corp

DHR

1,538,870

51.9

51.84

-0.1%

Express Scripts Inc

ESRX

1,154,700

55.61

55.68

0.1%

Polo Ralph Lauren Corp

RL

491,068

123.65

124.04

0.3%

Gilead Sciences Inc

GILD

1,215,778

42.47

39.53

-6.9%

NII Holdings Inc

NIHD

1,146,798

41.67

39.73

-4.7%

Amazon.com Inc

AMZN

261,900

180.13

186.37

3.5%

Microstrategy Inc

MSTR

315,062

134.48

140.5

4.5%

S&P 500 (SPY) has declined 4.1% from March 31 to June 17, while Soros’ top 10 new buys witnessed an average decline of 7.1%. Soros’ top position increases fared much better, declining only 2.2% on an average. If we consider weighted average returns, top new buys declined 5.6% while top position increases declined 2.7%.

The five best performing stocks among Soros’ top new buys and position increases are Charter Communications, CVS Caremark, BE Aerospace, Microstrategy and Visteon Corp. Here is a brief analysis of these stocks:

BE Aerospace is a leading manufacturer of cabin interior products for commercial aircrafts and business jets, and distributor of fasteners for the commercial aerospace markets. Its customers are almost all the world’s major airlines and airframe manufacturers and a variety of general aviation customers. B/E is organized into three divisions: Commercial Aircrafts, Consumables and Business jets.

I believe the stock is a good buy. The number of shipments for widebody aircrafts for 2013 has risen by 80% to 315 aircrafts over the 2010 numbers of 195 aircrafts. B/E Aerospace looks well positioned to take advantage of this upswing in the civil aerospace market, with it having over over 60% share of the widebody airliners market. Management focus on integration via the acquisitions of Satair and TSI should reap it results by providing it greater reach and product breadth. As per Consensus, current year EPS is estimated at $2.08 with forward EPS estimated at $2.58.

From a risk perspective, any adverse changes in the macroeconomic situation and associated GDP growth will have a direct impact on the commercial aerospace market. B/E generates more than half its revenue from the aircraft seats and cabin interior products, which are discretionary expenses by the airline. Also, for the month of April, the number of used business jets available for sale have showed an increasing trend, reducing potential of growth for new orders from this division.

Charter Communications is the fourth largest multiple operator in the U.S. (by number of video subscribers) with its operations across 27 states of the country.

I believe this one is a hold. Historically, video penetration has been CHTR’s lead product. With growth in same lagging, CHTR’s data subscription within its video base too has been limited. The industry has changed now with broadband being the main product. CHTR, having the most favorable fiber telco overlap, can have the highest competitive advantage, but only if its management can execute the right strategies. Intensifying competition in the industry makes its task tougher. From a balance sheet perspective, CHTR has higher leverage as well as higher exposure to floating interest rate debt, creating an interest risk exposure. It also significant bank debts maturing in 2014, creating a refinancing risk.

On the positive side, the expected sale of LA subscribers can provide an upside to the stock. Consolidation is also being expected by some analysts with CHTR being one of the potential sellers. CHTR has also been focusing on operational improvements and efficiencies that may result in significant cost savings over time.

CVS Caremark operates the largest integrated retail and pharmacy benefit services platform in the United States. As of December 31, 2010, it operated 44 retail specialty pharmacy stores, 18 specialty mail order pharmacies, and 4 mail service pharmacies located in 25 states, Puerto Rico, and the District of Columbia. Revenue is split almost evenly between the Retail Pharmacy and the Pharmacy Services segments.

I believe the stock is a good buy. CVC has been awarded the mail and specialty portions of the Federal Employee Program effective January 1, 2012. This program is worth $3bn in annual drug spends and approx. 10 mn. scripts. This contract builds over the multiple wins of over the over $11bn in contracts over the past two years, providing a high momentum to the company. Though there were concerns on impact of PBM streamlining initiatives on sales, no such impact has been observed, with over 50% of the claims coming being put on the destination platform. First phase of migration of clients to the platform has been also completed with no disruption to the client, which is a positive sign. Pricing continues to be a key concern for the industry, but CVC is not actively pursuing its early renewal strategy, as it had done in its prior years. The stock has a mean price target of $41.8 with a consensus EPS of $2.78 for current year and $3.16 for Dec 2012.

MicroStrategy is a global leader in Business Intelligence (BI) technology. MicroStartegy provides integrated reporting, analysis, and monitoring software that helps organizations worldwide make business decisions.

I believe the stock is a good buy. MicroStrategy has shown growth over 1Q2011 by building upon strong license revenues on account of bigger deal volumes as well as increase in medium and big sized deals. Domestic revenues increased by 45% year-over-year (yoy) and International License Revenues increased by 62% yoy. The expansion in headcount in the Sales team has increased the sales capacity of the company and has started having a visible impact. Launch of Visual Insight module that competes directly with Qlik and Tibco Spotfire. Microstrategy has also upgraded its BI platform such that integrates tightly with backend HR and Financial transactions. Consensus estimated EPS is $2.88 for current year, increasing to $4.6 Dec 2012.

Visteon is a leading global supplier of climate, interiors and electronic systems. The company was established in 2000 after its spin off from the Ford Motor Company (F). Geographically, North America, Europe and Asia account for 40%, 35% and 35% of sales respectively. Ford and Hyundai (GM:HYMLF) are its largest customers, contributing to a total of 54% its sales.

I believe the stock is a good buy. Riding on strong Q1 performance, Visteon is expected to continue its growth story further. Visteon started its restructuring in 2005. Through the same half decade, it has no UAW workers, no retiree healthcare obligations, 61% of its headcount is in low cost countries and $0.3 bn of net cash. It is also expected to be the beneficiary of the upcoming Japanese short supplies for Hyundai and Ford. Sales of Visteon’s Chinese JV, Yanfeng, were up 37% yoy, despite declining Chinese auto sales. Asset sales of Yanfeng by Visteon will bring further cash into the company. Median term full acquisition of Halla is also expected, further adding to Visteon’s strength. As per consensus estimates, EPS is expected to grown from $2.97 in current year to $5.17 next year.

Source: George Soros's Best Performing Top Buys